Novara Biotech reports quarterly revenue above the internal plan
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
Novara Biotech
Healthcare · Biotechnology
Updated UTC
410,77 US$
+5,46+1,35%
After hours412,82 US$+0,50%
| Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | 31,67 T | 37,26 T | 41,96 T | 48,31 T | 53,67 T |
| Gross profit | 18,76 T | 21,53 T | 23,9 T | 26,46 T | 32,34 T |
| Operating income | 6,26 T | 7,62 T | 7,85 T | 9,58 T | 11,72 T |
| Net income | 4,88 T | 5,63 T | 6,17 T | 5,78 T | 7,65 T |
Clinical-stage developer of oral therapies for autoimmune and metabolic disorders.
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
The company approved a multi-year capital program intended to shorten lead times for its largest customers.
Sector Desk
A sell-side desk kept a neutral rating while noting that near-term estimates already reflect steady execution.
Sector Desk
The board named an internal candidate with prior treasury and investor-relations experience to the role.
Sector Desk
The authorization covers a modest slice of the float and will be funded from operating cash flow.
Terminal Brief